Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN)
H. A. Ghofrani, R. Channick, M. Delcroix, N. Galiè, P. Jansa, F. O. Le Brun, S. Mehta, C. Mittelholzer, T. Pulido, B. K. S. Sastry, O. Sitbon, R. Souza, A. Torbicki, L. Rubin, G. Simonneau (Giessen, Germany; Boston, San Diego, United States Of America; Leuven, Belgium; Bologna, Italy; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; Le Kremlin Bicêtre, France; São Paulo, Brazil; ECZ-Otwock, Poland)
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Session: Pulmonary circulation: treatment
Session type: Oral Presentation
Number: 1786
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. A. Ghofrani, R. Channick, M. Delcroix, N. Galiè, P. Jansa, F. O. Le Brun, S. Mehta, C. Mittelholzer, T. Pulido, B. K. S. Sastry, O. Sitbon, R. Souza, A. Torbicki, L. Rubin, G. Simonneau (Giessen, Germany; Boston, San Diego, United States Of America; Leuven, Belgium; Bologna, Italy; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; Le Kremlin Bicêtre, France; São Paulo, Brazil; ECZ-Otwock, Poland). Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN). Eur Respir J 2013; 42: Suppl. 57, 1786
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: